Fig. 2
Histopathological appearance of hDPSC-treated mdx mice. Hematoxylin and eosin (H&E) staining of overall cross-sections of the tibialis anterior (TA) muscle from 12-week-old untreated mdx and high-dose hDPSC-treated mdx mice (a) and high magnification images containing low-dose hDPSC-treated mdx mice (b). Scale bars, 100 μm. c The average percentage of the frequency distribution of the myofiber area (μm2). Area values showed both frequency (% of total fibers) and distribution comparisons, paired t test. d Quantification of nuclear expansion as cross-section area (n = 3) and (e) quantification of the percentage of centrally nucleated fibers (CNFs) in the TA muscle (n = 4). Statistical differences compared to mdx mice (*P < 0.05, and **P < 0.01), paired t test. f Biodistribution of hDPSCs measured by Alu-PCR in the TA muscle, lung, and liver tissue from untreated mdx and repeated high-dose hDPSC-mdx mice 1 week after transplantation. Statistical differences compared to mdx mice (**P < 0.01, and ***P < 0.0005); ns, not significant, two-way ANOVA